THE RETROCYCLIN ANALOGUE RC-101 PREVENTS HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION OF A MODEL HUMAN CERVICOVAGINAL TISSUE CONSTRUCT.
This study by researchers at the University of Central Florida, University of Pittsburgh and UCLA School of Medicine demonstrated that MatTek’s EpiVaginal human vaginal-ectocervical tissue equivalent can be used to test the toxicity and efficacy of potential HIV-1 topical microbicides. Retrocyclins are cyclic antimicrobial peptides that exhibit potent activity towards a broad range of primary and laboratory-adapted strains of human immunodeficiency virus type 1 (HIV-1) in vitro. This study shows that RC-101, an analogue of retrocyclin, prevented HIV-1 infection in EpiVaginal, an organ-like construct of human cervicovaginal tissue, and retained full activity in the presence of vaginal fluid. The peptide remained within the cervicovaginal tissues throughout the 9-day incubation period without altering tissue viability, inducing damage or inducing the release of inflammatory cytokines. Collectively, these data support the potential development of RC-101 as a topical microbicide to prevent HIV-1 infection and transmission.
AIDS, Acquired immunodeficieny syndrome, Anti-microbial, Anti-microbial peptide, Antimicrobial, Antimicrobial peptide, Cervicovaginal tissue, Defensin, EpiVaginal, HIV, HIV-1, Human cervicovaginal tissue, Human immunodeficiency virus, Inflammation, Inflammatory, Inflammatory cytokines, Microbicide, Microbicides, RC-101, Retrocyclin, Retrocyclins, Theta defensin, Vagina
EpiVaginal, HIV-1 BaL, MTT, PM1, RC-101, TZM-bl
Request a copy of this paper, click here.